trial

Motive-specific Intervention for Negative Symptoms in Schizophrenia

NCTId NCT04793438
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 100 (estimated)
Sponsored by University of Zurich
Primary completion 2021-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2021-01-01
Primary completion
2021-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Motive-specific interventionSupportive conversations

Sponsors

University of ZurichLead Sponsor

Investigators

1
Birgit Kleim, Prof. Dr.Principal Investigator

Sites

1 total
Zurich, Switzerland

Facts & assertions

4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2021-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
Motive-specific intervention
drug
Supportive conversations
drug
lead_sponsor
University of Zurich
company
indication
Anhedonia
indication
Negative Type; Schizophrenic
indication
Psychotic Disorders
indication
investigator
Birgit Kleim, Prof. Dr.
person